D-0550-2023 Class II Ongoing
FDA drug recall D-0550-2023 was initiated by Northwind Pharmaceuticals LLC on Mar 16, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: 33 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 3, 2023
- Initiation Date
- Mar 16, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 33 bottles
Product description
Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide with the United States
Code information
Lot#: F107752201, Exp. Date 05/31/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0550-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026